Related Experiment Video

Updated: Oct 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet

N B Juran1

  • 1The Cleveland Clinic Foundation, OH 44195, USA.

American Heart Journal
|September 29, 1999
PubMed

Insights

New glycoprotein (GP) IIb-IIIa inhibitors reduce thrombotic events during percutaneous coronary intervention. However, these potent antithrombotic agents increase bleeding risk, necessitating careful nursing management to balance benefits and complications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nursing

Background:

  • Percutaneous coronary intervention (PCI) for coronary artery disease carries risks of thrombotic occlusion and ischemic complications.
  • Traditional antithrombotic agents like aspirin and heparin do not inhibit all thrombotic pathways.

Purpose of the Study:

  • To evaluate the role of novel glycoprotein (GP) IIb-IIIa inhibitors in PCI.
  • To highlight nursing challenges in managing patients receiving GP IIb-IIIa inhibitors, focusing on optimizing benefits and minimizing bleeding.

Main Methods:

  • Review of current antithrombotic strategies in PCI.
  • Analysis of the mechanism of action of GP IIb-IIIa inhibitors compared to traditional agents.
  • Examination of clinical outcomes and adverse events associated with GP IIb-IIIa inhibitors.

Main Results:

  • GP IIb-IIIa inhibitors (abciximab, eptifibatide, tirofiban) block the final common pathway of platelet aggregation.
  • Combination therapy with GP IIb-IIIa inhibitors, aspirin, and heparin reduces death, myocardial infarction, and urgent interventions.
  • An increased risk of bleeding complications, particularly at the femoral access site, is associated with GP IIb-IIIa inhibitors.

Conclusions:

  • GP IIb-IIIa inhibitors represent a significant advancement in antithrombotic therapy for PCI.
  • Effective nursing care is crucial for managing the dual goals of maximizing therapeutic benefits and preventing bleeding complications in patients receiving these agents.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...